Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $156.69.
A number of equities research analysts have commented on the company. Barclays restated an “overweight” rating and set a $148.00 price objective on shares of Abivax in a research report on Tuesday, September 22nd. Leerink Partners upped their price objective on shares of Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Guggenheim reiterated a “buy” rating and issued a $175.00 price objective on shares of Abivax in a research note on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Finally, Wedbush cut their price objective on Abivax from $140.00 to $118.00 and set a “neutral” rating for the company in a report on Tuesday, September 22nd.
Read Our Latest Stock Report on Abivax
Abivax Stock Up 5.8%
Shares of NASDAQ ABVX opened at $92.59 on Friday. Abivax has a 12 month low of $69.81 and a 12 month high of $148.83. The company has a market cap of $8.10 billion, a price-to-earnings ratio of -15.28 and a beta of 1.14. The business has a fifty day simple moving average of $105.10 and a 200-day simple moving average of $114.33.
Abivax (NASDAQ:ABVX – Get Free Report) last announced its earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The business had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, sell-side analysts expect that Abivax will post -4.04 EPS for the current fiscal year.
Hedge Funds Weigh In On Abivax
A number of hedge funds have recently added to or reduced their stakes in the company. Eversept Partners LP raised its holdings in Abivax by 42.0% in the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock worth $104,048,000 after acquiring an additional 276,589 shares during the period. Janus Henderson Group PLC boosted its holdings in Abivax by 31.6% during the first quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock valued at $98,007,000 after acquiring an additional 211,068 shares during the period. Bank of America Corp DE boosted its holdings in Abivax by 40.9% during the first quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock valued at $81,923,000 after acquiring an additional 213,440 shares during the period. Two Seas Capital LP bought a new stake in Abivax during the third quarter valued at about $66,996,000. Finally, Orbimed Advisors LLC grew its position in shares of Abivax by 26.6% in the first quarter. Orbimed Advisors LLC now owns 465,700 shares of the company’s stock valued at $51,856,000 after purchasing an additional 97,800 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.
About Abivax
Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.
Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.
See Also
- Five stocks we like better than Abivax
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
